Arthrosamid: A New Frontier in Knee Osteoarthritis Treatment available now in North Wales
I am extremely delighted to offer an innovative and pioneering non-surgical option for knee osteoarthritis treatment to North Wales patients at Spire Chesney Court and Abergele Clinic.
Osteoarthritis (OA) is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. As one of the most common forms of arthritis, it significantly impacts the quality of life for millions of individuals worldwide. Despite the prevalence of OA, treatment options remain limited, focusing primarily on pain management, physical therapy, and ultimately, surgical intervention. Currently, surgery remains a most reliable option to treat knee osteoarthritis in patients who exhausted all non-operative treatments. Although, there are number of patients who are either not suitable for surgery, fit for the surgery or not keen to have a major operation for various reasons. Unfortunately, options are extremely limited for such patients apart from very strong and potentially harmful painkillers. However, a novel treatment known as Arthrosamid is emerging as a promising alternative, offering hope for long-term relief without surgery for these patients.
What is Arthrosamid?
Arthrosamid is a unique, injectable hydrogel designed specifically for the treatment of knee osteoarthritis. Unlike traditional visco-supplementation therapies that involve injecting hyaluronic acid to lubricate the joint, Arthrosamid works by a different mechanism. It is composed of a non-biodegradable, non-absorbable polyacrylamide hydrogel that integrates into the synovial tissue (lining) of the knee joint, providing a cushioning effect and improving joint function.
Mechanism of Action
The polyacrylamide hydrogel in Arthrosamid acts by increasing the viscosity and elasticity of the synovial fluid, thereby enhancing its lubricating properties. Once injected, the hydrogel forms a cohesive network within the joint, which not only provides mechanical support but also reduces inflammation. This dual action helps in alleviating pain and improving mobility, offering patients a potential long-term solution to OA symptoms.
Clinical Evidence
Clinical trials and real-world evidence have demonstrated the efficacy and safety of Arthrosamid. In studies, patients treated with Arthrosamid reported significant improvements in pain relief and functional outcomes compared to baseline measurements. The treatment has shown to provide sustained benefits, with many patients experiencing relief lasting up to two years post-injection.
For instance, a study published in the *Journal of Orthopaedic Research* highlighted that Arthrosamid injections resulted in a marked reduction in knee pain and stiffness, along with an improvement in physical function. Furthermore, the hydrogel was well-tolerated with minimal adverse effects, making it a viable option for patients who are not candidates for surgery or those seeking an alternative to corticosteroids and other pharmacological treatments. The evidence also suggests that many patients have been able to avoid major surgery for upto three years with single injection.
Advantages Over Traditional Treatments
One of the main advantages of Arthrosamid over traditional visco-supplementation and pharmacological treatments is its durability. Traditional Cortisone or other injection can only provide pain-relief for few weeks or months, Arthrosamid’s effects can last significantly longer, up to three years due to its stable, non-degradable nature. This reduces the frequency of injections needed, thereby minimizing the risk of injection-related complications.
Additionally, Arthrosamid’s ability to integrate into the joint tissue provides a more natural form of joint support and lubrication, which can lead to better overall joint health. This contrasts with corticosteroids, which, although effective in reducing inflammation and pain, can have detrimental long-term effects on joint tissues.
The Future of OA Treatment
The introduction of Arthrosamid represents a significant advancement in the management of knee osteoarthritis. Its innovative approach addresses the limitations of existing treatments and offers a new avenue for patients seeking sustained relief from OA symptoms. As research continues and more data becomes available, Arthrosamid has the potential to become a cornerstone in the non-surgical treatment of osteoarthritis.
For patients suffering from the debilitating effects of knee osteoarthritis, Arthrosamid provides a beacon of hope. Its ability to deliver long-lasting pain relief and improve joint function could significantly enhance the quality of life for millions, paving the way for a future where OA is no longer a chronic burden but a manageable condition.
In conclusion, Arthrosamid is poised to revolutionize the treatment landscape for knee osteoarthritis. Its innovative hydrogel formulation offers a promising alternative to current therapies, with the potential for long-term symptom relief and improved joint health. As awareness and availability of this treatment grow, Arthrosamid could become a key player in the fight against osteoarthritis, providing much-needed relief for patients worldwide.
I have carefully scrutinised the Arthrosamid results, and safety data published and is very happy to incorporate this modality to offer to his patients in North Wales after a thorough clinical assessment and diagnosis. Unfortunately, this innovative treatment is not available on NHS. I will be very happy to discuss all treatment options available to these patients in detail.
I am available for consultation at Spire Chesney Court, Wrexham and Abergele Clinic on private basis by contacting my secretary on 01978 268065 or via e-mail: Anna.Gizzi@spirehealthcare.com